soluble endoglin  (Santa Cruz Biotechnology)

Journal: Journal of Clinical Medicine

Article Title: Molecular and Functional Cargo of Plasma-Derived Exosomes in Patients with Hereditary Hemorrhagic Telangiectasia

doi: 10.3390/jcm13185430

Figure Lengend Snippet: Antibodies for Western blot.

Article Snippet: Soluble Endoglin , Santa Cruz (Santa Cruz, CA, USA), SC-20072 , 1:200 in 5% BSA , Mouse , 61 kDa , Reducing , PVDF.

Techniques: Western Blot, Membrane

Journal: Journal of Clinical Medicine

Article Title: Molecular and Functional Cargo of Plasma-Derived Exosomes in Patients with Hereditary Hemorrhagic Telangiectasia

doi: 10.3390/jcm13185430

Figure Lengend Snippet: Soluble Endoglin levels in HD and HHT exosomes. ( A ) Representative Western blot of HD and HHT exosomes for the angiogenesis-related protein sENG and the exosomal marker TSG101. Numbers below lanes indicate band intensities of sENG normalized to TSG101 using lane normalization factors. ( B ) Normalized sENG values of HD and HHT exosomes (n = 17). Age- and gender-matched pairs of HDs and HHT patients whose plasma was used for exosome isolation are connected by a line. ( C ) Normalized sENG values of HHT exosomes (n = 17) were correlated to total exosomal protein levels, as determined by Bicinchoninic acid (BCA) assay. Spearman’s rank correlation coefficient (r) and correlation significance (p) were calculated. ( D ) Normalized sENG values of HD exosomes (n = 17) were correlated to the total exosomal protein levels, as determined by BCA assay. Pearson coefficient of correlation (R2) and correlation significance (p) are shown.

Article Snippet: Soluble Endoglin , Santa Cruz (Santa Cruz, CA, USA), SC-20072 , 1:200 in 5% BSA , Mouse , 61 kDa , Reducing , PVDF.

Techniques: Western Blot, Marker, Clinical Proteomics, Isolation, BIA-KA

Journal: Pulmonary Circulation

Article Title: Reduced circulating BMP9 and pBMP10 in hospitalized COVID‐19 patients

doi: 10.1002/pul2.12192

Figure Lengend Snippet: Circulating vascular injury and angiogenesis biomarkers after coronavirus disease 2019 (COVID‐19) infection. Plasma samples from healthy controls (0; n = 29), patients whose maximal respiratory support was supplemental oxygen (4, 5, 6; n = 49), and patients who required assisted ventilation (7, 8, 9; n = 22) were assessed for the following analytes using MesoScale Discovery multiplex immunoassays. (a) Serum amyloid A (SAA); (b) C‐reactive protein (CRP); (c) intercellular adhesion molecule 1 (ICAM‐1); (d) vascular cell adhesion molecule 1 (VCAM‐1); (e) E‐selectin; (f) thrombomodulin; (g) vascular endothelial growth factor A (VEGF‐A); (h) VEGFR1/Flt‐1; (i) placental growth factor (PlGF); (j) fibroblast growth factor (basic) (FGF(b)); (k) Tie‐2; (l) soluble endoglin (sENG) enzyme‐linked immunosorbent assay (ELISA); (m) bone morphogenetic protein 9 (BMP9) ELISA; (n) prodomain BMP10 (pBMP10) ELISA; (o) Pearson's correlation of circulating BMP9 and pBMP10 levels. p = 0.7415; (p) number of days patients were administered dexamethasone treatment before sample receipt; (q) Pearson's correlation of circulating BMP9 levels and dexamethasone treatment length. p = 0.3052; (r) circulating BMP9 levels of patient groups separated upon the time taken to be enrolled into the study. Sample receipt ≤7 days versus >7 days. All data presented as median–interquartile range. Kruskal–Wallis test. Dunn's multiple comparison test. ns, not significant; WHO, World Health Organization. p Values = *0.05; **0.01; ***0.001; ****0.0001.

Article Snippet: Enzyme‐linked immunosorbent assays (ELISAs) for BMP9 and pBMP10 were conducted as previously described., The soluble endoglin Quantikine assay (R&D Systems) was performed according to the manufacturer's instructions.

Techniques: Infection, Multiplex Assay, Enzyme-linked Immunosorbent Assay, Comparison